Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults

Click to read supplement. 

In this supplement to GI & Hepatology news, Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined. 

Topics include:

• IBS-D diagnosis and treatment challenges
• The role of microbial imbalance and altered gut microbiota
• A treatment option for relief of IBS-D symptoms

Click to read supplement. 

XIFI.0273.USA.18

Click to read supplement. 

In this supplement to GI & Hepatology news, Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined. 

Topics include:

• IBS-D diagnosis and treatment challenges
• The role of microbial imbalance and altered gut microbiota
• A treatment option for relief of IBS-D symptoms

Click to read supplement. 

XIFI.0273.USA.18

Click to read supplement. 

In this supplement to GI & Hepatology news, Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined. 

Topics include:

• IBS-D diagnosis and treatment challenges
• The role of microbial imbalance and altered gut microbiota
• A treatment option for relief of IBS-D symptoms

Click to read supplement. 

XIFI.0273.USA.18